Prof Pierosandro Tagliaferri, MD

Oncology — Magna Graecia University, Italy

LeadR Profile

Prof Pierosandro Tagliaferri, MD Magna Graecia University Italy
1 627 ScienceLeadR Reputation 1627
Network Map

Oncology

Subspecialties: Hematology - Pharmacy - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1987 - 2026

Source: PubMed

Magna Graecia University

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 406

Citations

Citations: 15 354 1st author: 16 Last author: 72 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Reply to the Letter by Mazzitelli M. et al. Regarding "Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase".
hematologic neoplasms, neoplasms, covid-19, pandemics
Cancer Med20260
Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.
lymphoma, follicular, hematology, antibodies, lymphoma, rituximab, network meta-analysis, therapeutics, antibodies, bispecific
Br J Haematol20262
CT-based radiomics as a non-invasive virtual biopsy for high PD-L1 expression prediction in non-small cell lung cancer.
cells, lung, neoplasms, carcinoma, non-small-cell lung, biopsy, lung neoplasms, small cell lung carcinoma
Cancer Imaging20260
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.
genes, epidermal growth factor, growth, cetuximab, genes, erbb-2, neoplasms, biomarkers, receptors, growth factor, therapeutics, colorectal neoplasms, liquid biopsy, mutation
ESMO Gastrointest Oncol20260
The role of the molecular tumor board: learnings from the ROME trial.
pharmaceutical preparations, neoplasms, therapeutics
NPJ Precis Oncol20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7
Phase 2 3
Phase 1 2

By status:

Completed 5
Recruiting 5
Active not recruiting 2

By type:

Interventional 12

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 11

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical study of sac TMT in people with breast cancer (MK 2870 032)
2024-520190-12-00 — triple negative breast neoplasms, safety, breast neoplasms, paclitaxel, neoplasms, drug therapy, respect, hormones, breast, neoadjuvant therapy, therapeutics, carboplatin, chemotherapy
Phase 3Recruiting2025
CAPRI 3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected metastatic colorectal cancer patients
2024-519322-20-00 — cetuximab, neoplasms, drug therapy, therapeutics, colorectal neoplasms, chemotherapy
Phase 3Recruiting2025
Phase III study in mCRC patients with RAS BRAF wild type tissue and RAS BRAF mutated in LIquid BIopsy to compare in first line therapy FOLFIRI plus CetuxiMAb or BevacizumaB
2024-517863-22-00 — cetuximab, genes, ras, bevacizumab, biopsy, drug therapy, diagnosis, therapeutics, tissues, liquid biopsy, chemotherapy
Phase 3Recruiting2024
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first line treatment of patients with unresectable left sided RAS B RAF wild type metastatic colorectal cancer (IMPROVE 2 trial)
2023-509551-14-00 — genes, ras, neoplasms, panitumumab, therapeutics, colorectal neoplasms
Phase 3Recruiting2024
ROMANCE Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer
NCT07381764 — vascular endothelial growth factor a, circulating tumor dna, cetuximab, trifluridine, pharmaceutical preparations, antineoplastic agents, neoplasms, drug combinations, bevacizumab, drug therapy, body weight, antibodies, monoclonal, therapeutics, colorectal neoplasms, irinotecan, chemotherapy
Phase 2Recruiting2026

LeadR Networks

Main global connection map